The article discusses the progress of psychiatry from the 1950s and 1960s, highlighting the breakthrough of antipsychotics and antidepressants. David Nutt criticizes the stagnation in psychiatric drug development over the last fifty years, attributing it to regulatory strictness and rigidity in research. While some experts like Eduard Vieta acknowledge improvements in side effect management, Nutt argues that innovation has not occurred, with newer drugs being merely refinements of previous ones. The article emphasizes the tension between views on advancements and the need for genuine breakthroughs in mental health treatments.
"In contrast to Nutt, Eduard Vieta argues that while new psychiatric drugs are variations of older ones, their side effects have been refined, leading to significant improvements for patients."
"Nutt critiques the last 50 years of psychiatric drug development, asserting that it has resulted mainly in variations on older medications without groundbreaking innovations."
Collection
[
|
...
]